Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2013 / Article
Special Issue

Acupuncture and Herbal Medicine for Cancer Patients

View this Special Issue

Research Article | Open Access

Volume 2013 |Article ID 935675 | https://doi.org/10.1155/2013/935675

Jing-Ru Weng, Li-Yuan Bai, Chang-Fang Chiu, Jing-Lan Hu, Shih-Jiuan Chiu, Chia-Yung Wu, "Cucurbitane Triterpenoid from Momordica charantia Induces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated Receptor γ Activation", Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 935675, 12 pages, 2013. https://doi.org/10.1155/2013/935675

Cucurbitane Triterpenoid from Momordica charantia Induces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated Receptor γ Activation

Academic Editor: Yoshiharu Motoo
Received20 Feb 2013
Revised24 May 2013
Accepted26 May 2013
Published13 Jun 2013


Although the antitumor activity of the crude extract of wild bitter gourd (Momordica charantia L.) has been reported, its bioactive constituents and the underlying mechanism remain undefined. Here, we report that 3β,7β-dihydroxy-25-methoxycucurbita-5,23-diene-19-al (DMC), a cucurbitane-type triterpene isolated from wild bitter gourd, induced apoptotic death in breast cancer cells through peroxisome proliferator-activated receptor (PPAR) γ activation. Luciferase reporter assays indicated the ability of DMC to activate PPARγ, and pharmacological inhibition of PPARγ protected cells from DMC's antiproliferative effect. Western blot analysis indicated that DMC suppressed the expression of many PPARγ-targeted signaling effectors, including cyclin D1, CDK6, Bcl-2, XIAP, cyclooxygenase-2, NF-κB, and estrogen receptor α, and induced endoplasmic reticulum stress, as manifested by the induction of GADD153 and GRP78 expression. Moreover, DMC inhibited mTOR-p70S6K signaling through Akt downregulation and AMPK activation. The ability of DMC to activate AMPK in liver kinase (LK) B1-deficient MDA-MB-231 cells suggests that this activation was independent of LKB1-regulated cellular metabolic status. However, DMC induced a cytoprotective autophagy presumably through mTOR inhibition, which could be overcome by the cotreatment with the autophagy inhibitor chloroquine. Together, the ability of DMC to modulate multiple PPARγ-targeted signaling pathways provides a mechanistic basis to account for the antitumor activity of wild bitter gourd.

1. Introduction

In Asia, bitter gourd (Momordica charantia L.) is widely used as a functional food to prevent and treat diabetes and associated complications [1]. In addition to the hypoglycemic effect, the antitumor activity of crude bitter gourd extract has also been reported in various types of cancer cells in vitro and in vivo [25]. Reported chemical constituents of bitter gourd include, but are not limited to, glycosides, saponins, alkaloids, fixed oils, triterpenes, polypeptides, and steroids (for review, see [6]). Wild bitter gourd, a wild species of M. charantia L., (M. charantia Linn. var. abbreviate), is native to several tropical areas of Asia, including southern Taiwan, where it is consumed not only as a vegetable but also as a herbal medicine. Recent studies have demonstrated that wild bitter gourd extracts exhibited multiple pharmacological activities associated with anti-inflammation and antidiabetics, including those of suppressing inflammatory response in macrophages [7], overcoming insulin resistance in skeletal muscle in fructose-fed rats [8], enhancing insulin signaling in skeletal muscle in high-fat-diet-fed mice [9], and upregulating mRNA expression of peroxisome proliferator-activated receptor (PPAR) α, PPARγ, and their target genes in mice [10]. Together, these activities might account for the ability of wild bitter gourd to improve metabolic syndrome in humans [11].

PPARγ regulates the expression of genes involved in the control of lipid metabolism and insulin sensitivity via the ligand-activated transcriptional activity [1215]. PPARγ ligands include naturally occurring fatty acids, 15-deoxy-delta12,14-prostaglandin J2 (PGJ2), and thiazolidinediones (TZDs), such as troglitazone and rosiglitazone [15]. Many of these PPARγ agonists exhibit antiproliferative activities against many types of cancer cells including those of colon, prostate, and breast, suggesting the potential use of these agents in cancer therapy or prevention [16]. Evidence suggests that PPARγ activation leads to the transcriptional suppression of a series of signaling effectors associated with tumorigenesis, including cell cycle regulators (cyclin D1, cyclin E, and cyclin-dependent kinase (CDK) 6) [17], antiapoptotic proteins (Bcl-2 and XIAP) [18], and cyclooxygenase- (COX-) 2 [19], thereby facilitating apoptotic death in cancer cells [20, 21]. Therefore, PPARγ is recognized as a therapeutically relevant target for cancer therapy [22, 23].

Although the health benefits of wild bitter gourd have been associated with PPARγ activation [10], bioactive constituents that contribute to this pharmacological effect, however, remain undefined. In this study, we investigated the mechanism underlying the antitumor effect of 3β,7β-dihydroxy-25-methoxycucurbita-5,23-diene-19-al (DMC; structure, Figure 1(a)), a cucurbitane triterpenoid isolated from wild bitter gourd with antileukemic activity [24]. We obtained first evidence that DMC induced apoptotic death in breast cancer cells, at least in part, through a PPARγ-dependent mechanism.

2. Materials and Methods

2.1. Plant Materials

DMC was isolated from the whole plant of M. charantia Linn. var. abbreviate collected in Pingtung County, Taiwan, in October 2008, and a voucher specimen (2008) has been deposited in the Department of Biological Science and Technology, China Medical University (Taichung, Taiwan). The identity and purity of purified DMC were verified by proton nuclear magnetic resonance (NMR) spectroscopy, high-resolution mass spectrometry, and 2D NMR spectrometry (Supplementary Material available online at http://dx.doi.org/10.115/2013/935675) using reported spectral data [25]. For in vitro experiments, DMC was dissolved in DMSO and was added to culture medium with a final DMSO concentration of less than 0.1%. Rabbit polyclonal antibodies against various biomarkers were obtained from the following sources: p-473Ser Akt, p-308Thr Akt, PARP, caspase-9, cyclin-dependent kinase (CDK) 6, p-2448Ser mTOR, mTOR, p-216Ser p70S6K, p-79Ser acetyl-CoA carboxylase (ACC), ACC, p70S6K, LC3, Atg7, GADD153, XIAP, GRP78, COX-2, Beclin 1, cyclin D1, p-172Thr adenosine monophosphate protein kinase (AMPK), AMPK, ERα, HIF1α, and NF-κB (Cell Signaling Technologies, Beverly, MA, USA); Akt and Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); β-actin (Sigma-Aldrich, St. Louis, MO, USA). The enhanced chemiluminescence (ECL) system for detection of immunoblotted proteins was from GE Healthcare Bioscience (Piscataway, NJ, USA). The GFP-LC3 and peroxisome proliferator-activated receptor response element (PPRE) x3-TK-Luc plasmids were kindly provided by Dr. Ching-Shih Chen at The Ohio State University. GW9662, chloroquine, and other chemical and biochemical reagents were obtained from Sigma-Aldrich unless otherwise is mentioned.

2.2. Cell Culture

MCF-7 and MDA-MB-231 human breast cancer cells were purchased from the American Type Culture Collection (Manasas, VA, USA). Cells were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA), 5 mg/mL of penicillin, 10 mg/mL of neomycin, and 5 mg/mL streptomycin at 37°C in a humidified incubator containing 5% CO2.

2.3. Cell Viability Analysis

Effect of test agents on cell viability was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays [26] in 6 replicates. Cells ( ) were seeded and incubated in 96-well, flat-bottomed plates in 10% FBS-supplemented DMEM/F12 for 24 h and were exposed to test agents at indicated concentrations for different time intervals. The medium was removed and replaced by 200 μL of 0.5 mg/mL MTT in 5% FBS-DMEM/F12, and cells were incubated at 37°C for 2 h. Medium was removed and the reduced MTT dye was solubilized in 200 μL/well DMSO. Absorbance was determined with a Synergy HT spectrophotometer (BioTek) at 570 nm.

2.4. Flow Cytometry

For assessment of apoptosis, cells were plated and treated with DMC at indicated concentration in 5% FBS-supplemented DMEM/F12 for 72 h. Cells were washed twice in ice-cold phosphate-buffered saline (PBS) and fixed in 70% cold ethanol for 4 h at 4°C, followed by spinning at 1200 rpm for 5 min and resuspending in ice-cold PBS containing 2% FBS. The cells were stained with Annexin V-FITC and propidium iodide according to the vendor’s protocols (BD Pharmingen, San Diego, CA, USA) and analyzed by using BD FACSAria flow cytometer (Becton, Dickinson and Company). Caspase-3 activation was assessed using a FITC Rabbit Anti-Active Caspase-3 kit (BD Pharmingen) according the manufacturer’s protocol.

2.5. Immunoblotting

Drug-treated cells were collected, washed with ice-cold PBS, and resuspended in lysis buffer, consisting of 20 mM Tris-HCl (pH 8), 137 mM NaCl, 1 mM CaCl2, 10% glycerol, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 100 μM 4-(2-aminoethyl)benzenesulfonyl fluoride, leupeptin at 10 μg/mL, and aprotinin at 10 μg/mL. Soluble cell lysates were collected after centrifugation at 1500 ×g for 5 min, and equivalent amounts of protein (60–100 μg) were resolved in 10% SDS-polyacrylamide gels. Bands were transferred to nitrocellulose membranes and blocked with 5% nonfat milk in PBS containing 0.1% Tween 20 (PBST) and incubated overnight with the corresponding primary antibody at 4°C. After washing with PBST three times, the membrane was incubated at room temperature for 1 h with the secondary antibody with PBST and visualized by enhanced chemiluminescence.

2.6. Transient Transfection

Plasmids were transiently transfected into cells by using the Fugene HD reagent (Roche) according to the manufacture’s protocol. After 24 h, the transfected cells were treated with DMC or DMSO control and subjected to fluorescent analysis or Western blotting.

2.7. Confocal Imaging

MCF-7 cells expressing GFP-LC3 (  mL) were seeded in each well of a six-well plate and treated with DMC at the indicated concentration for 3 h. Cells were fixed in 2% paraformaldehyde (Merck) for 30 min at room temperature and permeabilized with 0.1% Triton X-100 for 20 min. Cells were washed with PBS and then subjected to examination on a Leica TCS SP2 confocal microscope (Leica Biosystems Nussloch GmbH, Heidelberg, Germany) examination.

For PPARγ immunostaining, cells were fixed in 2% paraformaldehyde for 30 min at room temperature and permeabilized with 0.1% Triton X-100 for 20 min. After blocking with 1% bovine serum albumin (BSA), cells were incubated with mouse anti-human PPARγ antibody at 4°C overnight, followed by anti-mouse IgG at room temperature for 1 h, washed with PBS, and subjected to fluorescent microscopic examination.

2.8. Transmission Electron Microscope

Cells were fixed in a solution containing 2% paraformaldehyde, 2.5% glutaraldehyde, and 0.2 M sodium cacodylate for 1 h. Fixed cells were suspended in a buffered solution containing 1% osmic acid for 1 h, followed by dehydration in a graded ethanol series, washing with acetone, and embedding into EPON epoxy resin. Ultrathin sections (60–80 nm) were prepared on an ultramicrotome and double-stained with uranyl acetate and lead citrate. All sections were examined and photographed with a Hitach H-600 transmission electron microscope.

2.9. Statistical Analysis

All data are presented as means ± SD obtained from three independent experiments. Statistical differences were calculated using Student’s t-test, with the following symbols of significance level: , .

3. Results and Discussion

3.1. Antiproliferative Effect of DMC in Breast Cancer Cells

The dose- and time-dependent effects of DMC on cell viability were assessed in 2 human breast cancer cell lines, ERα-positive MCF-7, and ERα-negative MDA-MB-231, by MTT assays (Figures 1(b) and 1(c)). Relatively, MCF-7 cells were more sensitive to the antiproliferative effect of DMC than MDA-MB-231 cells, with IC50 values of 14.3 and 17.6 μM, respectively (Figures 1(b) and 1(c)).

3.2. DMC Induces Apoptosis through Caspase Activation

We obtained several lines of evidence that DMC suppressed the proliferation of MCF-7 cells by inducing apoptosis. First, annexin V-propidium iodide staining reveals a dose-dependent increases in the proportion of apoptotic cells (defined as annexin V+ cells) after DMC treatment (Figure 2(a)). Second, Western blot analysis showed that DMC induced PARP cleavage and caspase-9 activation in a dose-dependent manner in MCF-7 cells (Figure 2(b)). Third, flow cytometric analysis shows a dose-dependent increase in the expression of activated caspase-3 in response to DMC (Figure 2(c)), confirming the involvement of caspase activation in DMC-mediated apoptosis. Treatment with DMC at 10, 15, and 20 μM for 72 h increased the level of activated caspase-3, from 13% in the control group to 18%, 22%, and 30.5%, respectively ( compared to the DMSO control).

3.3. DMC Acts as a PPARγ Agonist

It has been reported that cucurbitane- and oleanane-type triterpenoids and saponins are potential active constituents of wild bitter gourd and that wild bitter gourd crude extracts activated PPARγ signaling in mice [10]. We hypothesized that the antitumor activity of DMC was associated with its ability to facilitate PPARγ activation. To corroborate this premise, MCF-7 cells were transiently transfected with PPRE-TK-Luc and Renilla plasmids and exposed to DMC at different concentrations or the positive control troglitazone at 50 μM for 24 h. As shown, the PPRE-luciferase reporter assay indicates that DMC at 15 and 20 μM increased the activity in PPARγ transactivation by 2.2- and 5.2-fold, respectively ( ), while troglitazone at 50 μM gave rise to a 2.8-fold increase (Figure 3(a)). Equally important, cotreatment with GW9662, a PPARγ inhibitor, protected cells from the suppressive effect of DMC on cell viability (Figure 3(b)). Although DMC did not alter the expression level of PPARγ (Figure 3(c), upper panel), two lines of evidence support the effect of DMC on PPARγ activation in MCF-7 cells. First, immunocytochemical analysis demonstrates the ability of DMC to facilitate the nuclear localization of PPARγ in a manner similar to that of troglitazone (Figure 3(c), lower panel).

Second, DMC was effective in modulating the expressions of various PPARγ-targeted gene products associated with cell cycle progression and apoptosis in MCF-7 cells, including cyclin D1, CDK6 [17], Bcl-2, XIAP [18], and COX-2 [19] (Figure 3(d)). In addition, the drug effect on the expression of NF-κB/p65 was interrogated in light of a recent report that PPARγ acts as an E-3 ligase targeting p65 degradation [27]. As shown, DMC suppressed the expression of NF-κB/p65 in a dose-dependent manner (Figure 3(d)). Moreover, the suppressive effect of DMC on estrogen receptor (ER) α expression is noteworthy (Figure 3(d)) as PGJ2 and TZD PPARγ agonists have been shown to disrupt ERα signaling by facilitating ERα degradation [28].

Previously, it was reported that PGJ2 and thiazolidinedione PPARγ agonists induce endoplasmic reticulum stress [29]. The ability of DMC to trigger this stress response was borne out by increased expression of two endoplasmic reticulum stress-associated markers, growth arrest- and DNA damage-inducible gene (GADD)153 (also known as CHOP), and GRP78 in MCF-7 cells (Figure 3(d)). GADD153 is a well-recognized endoplasmic reticulum stress-inducible transcription factor [30], and GRP78, a major endoplasmic reticulum chaperone, maintains endoplasmic reticulum integrity to mediate cell death when endoplasmic reticulum stress is beyond the tolerance of cell adaption [31].

3.4. DMC Induces Autophagy

In light of a recent report that PPARγ activation induces autophagy in breast cancer cells [15], we examined the effect of DMC on autophagy in MCF-7 cells. By using transmission electron microscopy, we found that exposure of MCF-7 cells to DMC at 10 or 15 μM for 24 h led to autophagosome formation in the cytoplasm (Figure 4(a)). During autophagy, the cytoplasmic form of microtubule-associated protein 1 light-chain (LC3-I) is processed and recruited to the autophagosomes, where LC3-II is generated via site-specific lipidation. Thus, to confirm this drug-induced autophagosome formation, we assessed the effect of DMC on LC3-II conversion in two ways. First, MCF-7 cells were transiently transfected with GFP-tagged LC3 (GFP-LC3) and exposed to DMSO, 15 μM DMC, or 100 nM rapamycin as a positive control. As observed by confocal fluorescence imaging, DMC induced the accumulation of LC3-positive puncta in the cytoplasm in a manner similar to that of rapamycin (Figure 4(b)). Second, Western blot analysis indicates that DMC treatment led to dose- and time-dependent increases in the abundance of endogenous LC3-II expression (Figures 4(c) and 4(d)). Moreover, our data show that this DMC-induced autophagy was associated with elevated expression levels of autophagy-related protein (Atg) 7 and Beclin 1 (a component of the class III phosphatidylinositol 3-kinase complex) (Figure 4(c)), both of which play a pivotal role in autophagy induction [32, 33].

3.5. DMC Targets mTOR Signaling via PPARγ and AMPK Activation

Interruption of mTOR signaling is known to stimulate autophagy [34]. To investigate the mechanistic link between mTOR and DMC-induced autophagy, we assessed the activation status of the Akt/mTOR signaling axis by examining the phosphorylation status of Akt at Thr308, Ser473, and mTOR, and the mTOR target p70S6K in DMC-treated MCF-7 cells. As shown, DMC decreased the phosphorylation levels of all of these kinases in a dose-dependent manner (Figure 5(a), left panel). It was also reported that thiazolidinedione PPARγ agonists induce autophagy through the activation of HIF1α [15], which led us to examine the expression of HIF1α. The result showed that DMC dose-dependently upregulated the expression of HIF1α (indicated by the 120 kDa band; Figure 5(a), left panel). To provide a mechanistic link among DMC-induced mTOR inhibition, PPARγ activation, and autophagy, we examined the effect of the PPARγ inhibitor GW9662 on these drug effects. Western blotting indicates that treatment of DMC or troglitazone, each at 15 μM, decreased phosphorylation of p70S6K, indicative of mTOR inhibition, accompanied by increased accumulation of LC3-II as compared to the vehicle control (Figure 5(a), right panel). Although GW9662 alone had no appreciable effect on either cellular response, it was able to reduce the activities of DMC and troglitazone to induce p70S6K dephosphorylation and the conversion of LC3-I to LC3-II (Figure 5(a), right panel).

In addition, it is well recognized that AMPK activation promotes autophagy via mTOR inhibition [35]. Western blot analysis indicated that DMC facilitated concentration-dependent increases in the phosphorylation levels of AMPK and its downstream target acetyl-CoA carboxylase (ACC) in both MCF-7 and MDA-MB-231 cells (Figure 5(b)). The ability of DMC to activate AMPK in MDA-MB-231 cells is noteworthy as this cell line is deficient in liver kinase B1 (LKB1) [36], an upstream kinase of AMPK. Interestingly, DMC treatment led to a concentration-dependent increases in the expression level of ACC in MDA-MB-231 cells, which plateaued at 15 μM, followed by a decrease at 20 μM. This change, however, was cell line-specific as it was not noted in MCF-7 cells, of which the underlying mechanism remained unclear.

Together, these findings suggest the ability of DMC to suppress mTOR signaling through the concerted action of Akt dephosphorylation and AMPK activation, which underlies the effect of DMC on autophagy induction.

3.6. Pharmacological Inhibition of Autophagy Enhances DMC-Induced Apoptotic Death

Autophagy has been reported to mediate a protective or enhancing effect on drug-induced cell death [37]. In light of the finding that autophagy acts as a survival signal in response to inhibitors of the PI3K-Akt-mTOR signaling axis [38], we examined the effect of chloroquine, an autophagy inhibitor, on DMC-mediated inhibition of MCF-7 cell proliferation. Chloroquine (CQ) inhibits autophagy at a later step in the pathway by blocking the fusion of autophagosome with lysosome and the subsequent lysosomal protein degradation [39]. As a consequence, treatment of CQ leads to increased LC3-II accumulation. As shown in Figure 6(a), exposure of MCF-7 cells to CQ, alone or in combination with DMC, showed a significantly higher accumulation of converted LC3-II relative to that of vehicle- or DMC-treated cells. This LC3-II accumulation is indicative of the inhibition of autophagy by CQ in MCF-7 cells. It is noteworthy that while the drug showed no antiproliferative activity against MCF-7 cells, chloroquine at 10 μM significantly enhanced the suppressive effect of DMC on viability of MCF-7 cells (Figure 6(b)). Annexin V-staining and Western blot analyses suggest that this increase in cytotoxicity was attributable to increased apoptosis as a result of autophagy inhibition (Figures 6(a) and 6(c)).

4. Discussion

Wild bitter gourd has been reported to exert anti-inflammatory [7], antioxidant [40], and hypoglycemic effects [41] in various experimental animal models. However, its active constituents contributing to these pharmacological effects have not been fully characterized. In this study, we demonstrated that DMC, a cucurbitane-type triterpene isolated from wild bitter gourd, acts as a PPARγ agonist. Although the activity of other cucurbitane-type triterpenes in modulating PPARγ activity remains to be investigated, the ability of DMC to activate PPARγ might underlie the hypoglycemic effect of wild bitter gourd crude extracts in diabetic mice [41].

Several lines of evidence indicate that PPARγ plays a pivotal role in mediating DMC’s antiproliferative activity in breast cancer cells. First, inhibition of PPARγ by the pharmacological inhibitor GW9662 protected cells from the inhibitory effect of DMC on the viability of MCF-7 cells (Figure 3(b)). Second, DMC suppressed the expression of a series of PPARγ-targeted signaling effectors that govern cell cycle progression, proliferation, and survival, including cyclin D1, CDK6, Bcl-2, XIAP, COX-2, NF-κB, and ERα (Figure 3(d)). Particularly, the downregulation of ERα expression is noteworthy since ERα has been shown to bind to PPRE and negatively interfere with PPARγ signaling in breast cancer cells [42]. Thus, this ERα-ablating effect might account for the higher sensitivity of MCF-7 cells relative to MDA-MB-231 cells to DMC (Figure 1(b)). Third, DMC induced autophagy through mTOR inhibition (Figures 4 and 5), which is reminiscent with that reported with TZD PPARγ agonists in breast cancer cells [15].

mTOR, a central cell growth regulator that integrates growth factor and nutrient signals [43], is positively and negatively regulated by Akt and AMPK, respectively. This DMC-facilitated mTOR downregulation is likely attributable to the concerted action of DMC to facilitate Akt dephosphorylation and AMPK activation (Figure 5). The ability of DMC to activate AMPK is noteworthy as AMPK is a key energy sensor and regulates cellular metabolism to maintain energy homeostasis [44]. Previously, TZD PPARγ agonists were reported to induce PPARγ-independent AMPK activation through changes in cellular energy state [45, 46]. However, the finding that DMC was equally effective in activating AMPK in LKB1-deficient MDA-MB-231 and MCF-7 cells suggests that this activation might be independent of the cellular metabolic status as LKB1 is activated in response to environmental nutrient changes [47]. Thus, the mode of AMPK activation by DMC warrants further investigation.

The Akt/mTOR pathway is often dysregulated in malignant cells, thus representing an important target for cancer prevention and therapy [48]. The concurrent suppressive effect of DMC on Akt and mTOR activation is noteworthy, because it circumvents the feedback activation that results from mTOR inhibition, a problem associated with rapamycin-based mTOR inhibitors [49]. From a clinical perspective, the ability of DMC to concurrent target Akt and mTOR underlies its translational potential as a chemopreventive agent. Nonetheless, consistent with the reported effect of mTOR inhibitors and many other anticancer agents, DMC induced a cytoprotective autophagy that decreased DMC’s antiproliferative potency, which, however, could be overcome by the co-treatment with the autophagy inhibitor chloroquine (Figure 6). Further in vivo studies are needed to better understand the role of DMC, alone or in combination with other agent, in breast cancer prevention and treatment.

5. Conclusion

There has been growing interest in the use of wild bitter gourd as a dietary supplement for the treatment of various illnesses in light of its diverse pharmacological effects, including hypoglycemic, anti-inflammatory, antibacterial, antiviral, and antitumor activities. However, despite recent advances in gaining understanding of the health beneficial effects of this herbal medicine, information regarding the mode of action of its bioactive ingredients is lacking or fragmentary. In this study, the activity of DMC isolated from wild bitter gourd in PPARγ activation was characterized for the first time. As the role of PPARγ in regulating lipid metabolism, insulin sensitivity, apoptosis, and cell differentiation is well recognized, the ability of DMC to modulate multiple PPARγ-targeted signaling pathways provides a molecular basis to account for the hypoglycemic and antitumor activities of wild bitter gourd. Today, processed bitter gourd in the form of capsules or tablets is used by natural health practitioners, which like many other herbal medicine suffers from difficulty in quality control due to high variability of bioactive compounds involved. From a clinical perspective, wild bitter gourd extracts enriched in DMC and related compounds, of which the contents could be quantified by chromatographic fingerprint analysis, will provide a better alternative to capsules or tablets for disease management.

Conflict of Interests

The authors declare no competing financial interests.


This work was supported in part by Grants from the Taiwan Department of Health, China Medical University Hospital Cancer Research of Excellence (DOH102-TD-C-111-005) and National Science Council Grant (NSC 99-2320-B-039-007-MY2, NSC 101-2320-B-039-029-MY2). The authors would like to thank Core Facility Center, Office of Research and Development (Taipei Medical University) for the technical support of TEM.

Supplementary Materials

1D, 2D NMR, and Mass spectra of 3beta,7beta-dihydroxy-25-methoxycucurbita-5, 23-diene-19-al (DMC).

  1. Supplementary Material


  1. R. B. Ray, A. Raychoudhuri, R. Steele, and P. Nerurkar, “Bitter Melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis,” Cancer Research, vol. 70, no. 5, pp. 1925–1931, 2010. View at: Publisher Site | Google Scholar
  2. C. Jilka, B. Strifler, and G. W. Fortner, “In vivo antitumor activity of the bitter melon (Momordica charantia),” Cancer Research, vol. 43, no. 11, pp. 5151–5155, 1983. View at: Google Scholar
  3. R. Soundararajan, P. Prabha, U. Rai et al., “Antileukemic potential of Momordica charantia seed extracts on human myeloid leukemic HL60 cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 732404, 10 pages, 2012. View at: Publisher Site | Google Scholar
  4. P. Ru, R. Steele, P. V. Nerurkar, N. Phillips, and R. B. Ray, “Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model,” Cancer Prevention Research, vol. 4, no. 12, pp. 2122–2130, 2011. View at: Publisher Site | Google Scholar
  5. V. C. Brennan, C. Wang, and W. Yang, “Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC-α serine/threonine-protein kinase signaling,” Journal of Medicinal Food, vol. 15, no. 4, pp. 325–334, 2012. View at: Publisher Site | Google Scholar
  6. P. Scartezzini and E. Speroni, “Review on some plants of Indian traditional medicine with antioxidant activity,” Journal of Ethnopharmacology, vol. 71, no. 1-2, pp. 23–43, 2000. View at: Publisher Site | Google Scholar
  7. C. K. Lii, H. W. Chen, W. T. Yun, and K. Liu, “Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviata ser.) fruit extracts on inflammatory responses in RAW 264.7 macrophages,” Journal of Ethnopharmacology, vol. 122, no. 2, pp. 227–233, 2009. View at: Publisher Site | Google Scholar
  8. C. C. Shih, C. H. Lin, W. L. Lin, and J. Wu, “Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats,” Journal of Ethnopharmacology, vol. 123, no. 1, pp. 82–90, 2009. View at: Publisher Site | Google Scholar
  9. Z. Q. Wang, X. H. Zhang, Y. Yu et al., “Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice,” Journal of Nutritional Biochemistry, vol. 22, no. 11, pp. 1064–1073, 2011. View at: Publisher Site | Google Scholar
  10. C. Y. Chao, M. C. Yin, and C. J. Huang, “Wild bitter gourd extract up-regulates mRNA expression of PPARα, PPARγ and their target genes in C57BL/6J mice,” Journal of Ethnopharmacology, vol. 135, no. 1, pp. 156–161, 2011. View at: Publisher Site | Google Scholar
  11. C. H. Tsai, E. C. Chen, H. S. Tsay, and C. J. Huang, “Wild bitter gourd improves metabolic syndrome: a preliminary dietary supplementation trial,” Nutrition Journal, vol. 11, no. 1, p. 4, 2012. View at: Publisher Site | Google Scholar
  12. S. Jeong and M. Yoon, “17β-Estradiol inhibition of PPARγ-induced adipogenesis and adipocyte-specific gene expression,” Acta Pharmacologica Sinica, vol. 32, no. 2, pp. 230–238, 2011. View at: Publisher Site | Google Scholar
  13. Y. Jiang, Y. Huang, C. Cheng et al., “Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells,” Experimental and Molecular Pathology, vol. 91, no. 3, pp. 768–774, 2011. View at: Publisher Site | Google Scholar
  14. R. Rusinova, K. F. Herold, R. Lea Sanford, D. V. Greathouse, H. C. Hemmings, and O. S. Andersen, “Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery,” Journal of General Physiology, vol. 138, no. 2, pp. 249–270, 2011. View at: Publisher Site | Google Scholar
  15. J. Zhou, W. Zhang, B. Liang et al., “PPARγ activation induces autophagy in breast cancer cells,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 11, pp. 2334–2342, 2009. View at: Publisher Site | Google Scholar
  16. J. R. Weng, C. Y. Chen, J. J. Pinzone, M. D. Ringel, and C. S. Chen, “Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 401–413, 2006. View at: Publisher Site | Google Scholar
  17. N. H. Yu, Y. R. Lee, E. M. Noh et al., “Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPARγ) ligand,” Cell Biology International, vol. 32, no. 8, pp. 906–912, 2008. View at: Publisher Site | Google Scholar
  18. K. Fuenzalida, R. Quintanilla, P. Ramos et al., “Peroxisome proliferator-activated receptor γ up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis,” Journal of Biological Chemistry, vol. 282, no. 51, pp. 37006–37015, 2007. View at: Publisher Site | Google Scholar
  19. J. J. Liu, P. Q. Liu, D. J. Lin et al., “Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-γ agonists induced apoptosis in human monocyte leukemia cells in vitro,” Annals of Hematology, vol. 86, no. 3, pp. 173–183, 2007. View at: Publisher Site | Google Scholar
  20. R. E. Teresi, C. W. Shaiu, C. S. Chen, V. K. Chatterjee, K. A. Waite, and C. Eng, “Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone,” International Journal of Cancer, vol. 118, no. 10, pp. 2390–2398, 2006. View at: Publisher Site | Google Scholar
  21. C. Colin, S. Salamone, I. Grillier-Vuissoz et al., “New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines,” Breast Cancer Research and Treatment, vol. 124, no. 1, pp. 101–110, 2010. View at: Publisher Site | Google Scholar
  22. H. P. Koeffler, “Peroxisome proliferator-activated receptor γ and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003. View at: Google Scholar
  23. M. H. Fenner and E. Elstner, “Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 557–568, 2005. View at: Publisher Site | Google Scholar
  24. J. Zhang, Y. Huang, T. Kikuchi et al., “Cucurbitane triterpenoids from the leaves of Momordica charantia, and their cancer chemopreventive effects and cytotoxicities,” Chemistry and Biodiversity, vol. 9, no. 2, pp. 428–440, 2012. View at: Publisher Site | Google Scholar
  25. D. A. Mulholland, V. Sewram, R. Osborne, K. H. Pegel, and J. D. Connolly, “Cucurbitane triterpenoids from the leaves of Momordica foetida,” Phytochemistry, vol. 45, no. 2, pp. 391–395, 1997. View at: Publisher Site | Google Scholar
  26. J. R. Weng, C. H. Tsai, S. K. Kulp, and C. S. Chen, “Indole-3-carbinol as a chemopreventive and anti-cancer agent,” Cancer Letters, vol. 262, no. 2, pp. 153–163, 2008. View at: Publisher Site | Google Scholar
  27. Y. Hou, F. Moreau, and K. Chadee, “PPARγ is an E3 ligase that induces the degradation of NFκB/p65,” Nature Communications, vol. 3, Article ID 1300, 2012. View at: Publisher Site | Google Scholar
  28. J. Lecomte, S. Flament, S. Salamone et al., “Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 437–451, 2008. View at: Publisher Site | Google Scholar
  29. S. M. Weber, K. T. Chambers, K. G. Bensch, A. L. Scarim, and J. A. Corbett, “PPARγ ligands induce ER stress in pancreatic β-cells: ER stress activation results in attenuation of cytokine signaling,” American Journal of Physiology, vol. 287, no. 6, pp. E1171–E1177, 2004. View at: Publisher Site | Google Scholar
  30. S. Oyadomari and M. Mori, “Roles of CHOP/GADD153 in endoplasmic reticulum stress,” Cell Death and Differentiation, vol. 11, no. 4, pp. 381–389, 2004. View at: Publisher Site | Google Scholar
  31. D. Ron and P. Walter, “Signal integration in the endoplasmic reticulum unfolded protein response,” Nature Reviews Molecular Cell Biology, vol. 8, no. 7, pp. 519–529, 2007. View at: Publisher Site | Google Scholar
  32. D. J. Klionsky, J. M. Cregg, W. A. Dunn Jr. et al., “A unified nomenclature for yeast autophagy-related genes,” Developmental Cell, vol. 5, no. 4, pp. 539–545, 2003. View at: Publisher Site | Google Scholar
  33. X. H. Liang, S. Jackson, M. Seaman et al., “Induction of autophagy and inhibition of tumorigenesis by beclin 1,” Nature, vol. 402, no. 6762, pp. 672–676, 1999. View at: Publisher Site | Google Scholar
  34. A. J. Meijer and P. F. Dubbelhuis, “Amino acid signalling and the integration of metabolism,” Biochemical and Biophysical Research Communications, vol. 313, no. 2, pp. 397–403, 2004. View at: Publisher Site | Google Scholar
  35. A. J. Meijer and P. Codogno, “AMP-activated protein kinase and autophagy,” Autophagy, vol. 3, no. 3, pp. 238–240, 2007. View at: Google Scholar
  36. Z. Shen, X. F. Wen, F. Lan, Z. Shen, and Z. Shao, “The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma,” Clinical Cancer Research, vol. 8, no. 7, pp. 2085–2090, 2002. View at: Google Scholar
  37. P. Codogno and A. J. Meijer, “Autophagy and signaling: their role in cell survival and cell death,” Cell Death and Differentiation, vol. 12, supplement 2, pp. 1509–1518, 2005. View at: Publisher Site | Google Scholar
  38. Q. W. Fan, C. Cheng, C. Hackett et al., “Akt and autophagy cooperate to promote survival of drug-resistant glioma,” Science Signaling, vol. 3, no. 147, p. ra81, 2010. View at: Publisher Site | Google Scholar
  39. T. Shintani and D. J. Klionsky, “Autophagy in health and disease: a double-edged sword,” Science, vol. 306, no. 5698, pp. 990–995, 2004. View at: Publisher Site | Google Scholar
  40. H. B. Li, C. C. Wong, K. W. Cheng, and F. Chen, “Antioxidant properties in vitro and total phenolic contents in methanol extracts from medicinal plants,” LWT-Food Science and Technology, vol. 41, no. 3, pp. 385–390, 2008. View at: Publisher Site | Google Scholar
  41. X. Q. Yuan, X. H. Gu, J. Tang, and J. Wasswa, “Hypoglycemic effect of semipurified peptides from Momordica charantia L. var. Abbreviata Ser. in alloxan-induced diabetic mice,” Journal of Food Biochemistry, vol. 32, no. 1, pp. 107–121, 2008. View at: Publisher Site | Google Scholar
  42. D. Bonofiglio, S. Gabriele, S. Aquila et al., “Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells,” Clinical Cancer Research, vol. 11, no. 17, pp. 6139–6147, 2005. View at: Publisher Site | Google Scholar
  43. J. Yan, H. Yang, G. Wang et al., “Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling,” Autophagy, vol. 6, no. 1, pp. 67–73, 2010. View at: Publisher Site | Google Scholar
  44. J. Kim, M. Kundu, B. Viollet, and K. Guan, “AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1,” Nature Cell Biology, vol. 13, no. 2, pp. 132–141, 2011. View at: Publisher Site | Google Scholar
  45. N. K. LeBrasseur, M. Kelly, T. Tsao et al., “Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues,” American Journal of Physiology, vol. 291, no. 1, pp. E175–E181, 2006. View at: Publisher Site | Google Scholar
  46. W. H. Lee and S. G. Kim, “AMPK-dependent metabolic regulation by PPAR agonists,” PPAR Research, vol. 2010, Article ID 549101, 10 pages, 2010. View at: Publisher Site | Google Scholar
  47. D. B. Shackelford and R. J. Shaw, “The LKB1-AMPK pathway: metabolism and growth control in tumour suppression,” Nature Reviews Cancer, vol. 9, no. 8, pp. 563–575, 2009. View at: Publisher Site | Google Scholar
  48. C. Bartholomeusz and A. M. Gonzalez-Angulo, “Targeting the PI3K signaling pathway in cancer therapy,” Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 121–130, 2012. View at: Publisher Site | Google Scholar
  49. K. E. O'Reilly, F. Rojo, Q. She et al., “mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt,” Cancer Research, vol. 66, no. 3, pp. 1500–1508, 2006. View at: Publisher Site | Google Scholar

Copyright © 2013 Jing-Ru Weng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.